Evaluate EGFR Mutation Status and Impact Factors in North China

A Retrospective Study on Real-world EGFR Mutation Testing Practice Status and Impact Factors in Patients With Advanced NSCLC in North China

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02620657

Enrollment

2809

Registered

2015-12-03

Start date

2015-12-31

Completion date

2017-11-08

Last updated

2019-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Brief summary

Approximately 3000 advanced NSCLC patients, who fulfil the inclusion/exclusion criteria, will be recruited by 30 sites in North China.

Detailed description

Approximately 3000 advanced NSCLC patients will be recruited , and the medical information of recruited patients must be recorded in the hospital electronic system from Jan 1st 2014 to Dec 31st 2014 .The study will focus on the EGFR testing rate in adenocarcinoma patients，so the collecting data for non-adenocarcinoma patients will be controlled in less than 10% for each site.

Interventions

OTHERNon interventional study

Non interventional study

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Histological or cytological confirmed NSCLC; * Patients were diagnosed with advanced NSCLC from Jan 1st 2014 to Dec 31st 2014; * Researchers should collect the records of consecutive NSCLC patients in each site.

Exclusion criteria

* Any patients without NSCLC diagnosis; * Any patients which were diagnosed with advanced NSCLC before Jan 1st 2014 or after Dec 31st 2014.

Design outcomes

Primary

Measure	Time frame
To investigate the proportion of advanced NSCLC patients who performed EGFR mutation test	2014.01.01-2014.12.31

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026